Early treatment failure is associated with specific genetic abnormalities in MCL, namely mutations of KMT2D and TP53 [8], deletions of RB1, CDKN2A (p16), TP53 and CDKN1B [9], as well as a high-risk MCL international prognostic index (MIPI)-c or high p53 expression [10]. The gene discussed is CDKN2A; the disease is mantle cell lymphoma.